CD5+ diffuse large B-cell lymphoma: a narrative review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34284686/
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, and cell surface cluster of differentiation (CD) 5 expression may represent a distinct subset. Here, we provide a narrative review of...
Computed Tomography Imaging Findings for Predicting Histological Subtypes and Clinical Outcomes in Patients With Head and Neck Nodal Involvement of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34297517/
Objective: This study aimed to assess computed tomography (CT) imaging findings for predicting the histological subtypes and clinical outcomes in patients with head and neck nodal involvement of diffuse large...
GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/β-catenin signaling pathway - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34280359/
Glycoprotein non-metastatic melanoma protein B (GPNMB) has been confirmed to be related to the pathogenesis of tumors. However, the potential impact of GPNMB on the progression of diffuse large B-cell...
Cardiovascular Outcomes in the Patients With Primary Central Nervous System Lymphoma: A Multi-Registry Based Cohort Study of 4,038 Cases - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34290986/
Primary central nervous system lymphoma (PCNSL) is a rare but highly aggressive non-Hodgkin lymphoma. Treatment-related cardiovascular lesion has become one of the most common complications in patients with tumor. However,...
Advances in Immunotherapy for Diffuse Large B Cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34264504/
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease that is normally treated with combination chemotherapy combined with the anti-CD20 monoclonal antibody rituximab. Although about two-thirds of patients are...
-
Naveed Saleh, MD, MS – Skipta Team4yrKey Points • In the current review, authors examined the current milieu for DLBCL treatment including monoclonal antibodies, antibody–drug conjugates, bispecific antibodies and chimeric antigen receptor (CAR) T cells. Although the Show More